Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors.

Savoca A, Zindel D, Polanski R, Kostomiris DH, Pirmoradian M, Swaih AM, Talbot S, Floc'h N, Winlow P, Davey PRJ, Longmire D, Wadforth E, Lewis HJ, Smith A, Lipka R, Wilson J, Britton DJ, Dokal AD, Smith R, Thomson C, McCoull W

Open source

DOI: 10.1158/1535-7163.mct-25-0082
Published: 2026 Jul 2
Container: Molecular cancer therapeutics
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1535-7163.mct-25-0082,
  title = {Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors.},
  author = {Savoca A and Zindel D and Polanski R and Kostomiris DH and Pirmoradian M and Swaih AM and Talbot S and Floc'h N and Winlow P and Davey PRJ and Longmire D and Wadforth E and Lewis HJ and Smith A and Lipka R and Wilson J and Britton DJ and Dokal AD and Smith R and Thomson C and McCoull W},
  year = {2026},
  journal = {Molecular cancer therapeutics},
  doi = {10.1158/1535-7163.mct-25-0082},
  url = {https://doi.org/10.1158/1535-7163.mct-25-0082}
}

RIS

TY  - JOUR
TI  - Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors.
AU  - Savoca A
AU  - Zindel D
AU  - Polanski R
AU  - Kostomiris DH
AU  - Pirmoradian M
AU  - Swaih AM
AU  - Talbot S
AU  - Floc'h N
AU  - Winlow P
AU  - Davey PRJ
AU  - Longmire D
AU  - Wadforth E
AU  - Lewis HJ
AU  - Smith A
AU  - Lipka R
AU  - Wilson J
AU  - Britton DJ
AU  - Dokal AD
AU  - Smith R
AU  - Thomson C
AU  - McCoull W
PY  - 2026
JO  - Molecular cancer therapeutics
DO  - 10.1158/1535-7163.mct-25-0082
UR  - https://doi.org/10.1158/1535-7163.mct-25-0082
ER  -

APA

A, S., D, Z., R, P., DH, K., M, P., AM, S., S, T., N, F., P, W., PRJ, D., D, L., E, W., HJ, L., A, S., R, L., J, W., DJ, B., AD, D., R, S., C, T., & W, M. (2026). Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors.. Molecular cancer therapeutics. https://doi.org/10.1158/1535-7163.mct-25-0082

Source records

pubmed · retrieved 2026-09-27T13:22:21.793Z
europe-pmc · retrieved 2026-09-27T13:22:21.809Z